HMBD-001 is our lead precision therapy program that targets HER3, a potent driver of tumor growth and resistance against cancer drugs.

Why HER3?

A member of the EGFR family of receptors, HER3 activation is driven by the dimerization with HER2 or EGFR, triggering the MAPK/PI3K signaling pathway that promotes cancer cell division and growth. Dimerization is favored in the presence of the ligand, neuregulin 1 (NRG1) or HER2/EGFR overexpression. HER3 has received attention in recent years as it has been implicated in a significant number of cancers and in acquired resistance to other therapies. Moreover, a subpopulation of cancer patients has been identified with NRG1 fusions in their tumors; that is, the hybridization of the NRG1 gene with another gene to produce NRG1 fusion proteins that potently activate HER3.

Though a highly promising target, HER3 has proved difficult to drug effectively. Previous attempts to block the HER3 receptor have not proven to be efficacious, likely due to the inability of these antibodies to completely prevent dimerization of HER3, since dimerization is not fully dependent on NRG1 binding.

Made with BioRender

Engineer with Precision

Developed with our Rational Antibody Discovery platform, HMBD-001 is a unique antibody engineered to bind strongly and specifically to the dimerization interface of HER3, thereby interfering with HER3’s ability to dimerize and fully blocking its activation, regardless of NRG1 binding.

This gives HMBD-001 a novel mechanism of action for inhibiting tumor growth and drug resistance in HER3-driven cancers. Preclinical models have shown that HMBD-001 potently inhibits the activation of the MAPK/PI3K signaling pathway – and consequently, prevents tumor growth and drug resistance.

Develop with Precision

HMBD-001 has broad potential across multiple tumor types, however, optimal clinical development requires a phased strategy to demonstrate benefit in patients with gene signatures most likely to benefit from HMBD-001.

Through integrative AI-powered analyses of robust datasets, we have identified biomarkers indicative of patient populations who may benefit most from HMBD-001.

HMBD-001 is currently in clinical trials in the UK (NCT05057013), and in Australia evaluating patients with squamous non-small cell lung cancer (NCT05910827) and patients with genetic aberrations in HER3 signaling (NCT05919537).

Publications & Posters

Related News